Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis.
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D006658:Histoplasma / Q000254:growth & development / Q000472:pathogenicity; D006660:Histoplasmosis / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006801:Humans; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D007962:Leukocytes / Q000276:immunology / Q000378:metabolism; D015289:Leukotrienes / Q000096:biosynthesis / Q000276:immunology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008172:Lung Diseases, Fungal / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000096:biosynthesis; D002722:Chlorobenzenes
D016207:Cytokines; D007211:Indoles; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D009569:Nitric Oxide; C060893:MK-886; D002722:Chlorobenzenes